Table 4.

Relative advantages and disadvantages of factor XII or factor XI as targets for new anticoagulants

Factor XIIFactor XI
Epidemiological dataWeakStronger
Risk for bleedingNoneLow
Level of evidence for role in thrombosisPreclinicalPhase 2
Potential for bypassing inhibitionThrombin-mediated activation of factor XI could bypass factor XII inhibitionNone
Potential for off target effectsMay modulate inflammation by inhibiting bradykinin generationUnlikely